SCHEDULE 13G: AstralBio CEO Patrick Crutcher Discloses 7.2% Beneficial Ownership in IBIO, Inc. Following Licensing Agreement and Private Placements

Patrick J. Crutcher, CEO and majority shareholder of AstralBio, Inc., has reported a 7.2% beneficial ownership stake in IBIO, Inc., primarily through shares issued in connection with an exclusive licensing agreement and prior private placements.

Summary

• Patrick J. Crutcher, the Chief Executive Officer and majority shareholder of AstralBio, Inc., has filed a Schedule 13G disclosing beneficial ownership of 714,713 shares of IBIO, Inc. Common Stock.
• This ownership represents 7.2% of IBIO's outstanding Common Stock.
• The beneficial ownership includes 264,087 shares indirectly owned through AstralBio, Inc., which were issued by IBIO on January 28, 2025, as part of an exclusive Licensing Agreement entered into on December 31, 2024.
• Additionally, Mr. Crutcher directly received 175,438 shares and warrants to purchase up to 175,438 shares (subject to a 9.99% beneficial ownership blocker) on April 1, 2024, via a private placement transaction.
• He was also granted 133,000 options to purchase Common Stock on April 25, 2024, in connection with a consulting agreement, with 99,750 of these options exercisable within 60 days of the filing date.
• The ownership percentage is calculated based on 9,149,470 shares outstanding as of November 12, 2024, plus an additional 240,807 shares sold in a private placement on January 10, 2025, and the 264,087 shares issued to AstralBio on January 28, 2025.

Sentiment

Score: 6

Explanation: The document is primarily factual, reporting a significant beneficial ownership stake resulting from strategic agreements and private placements. The establishment of a licensing agreement and the associated equity issuance could be viewed positively as a strategic development, but the filing itself is neutral in tone.

Risks

• The Reporting Person disclaims beneficial ownership of shares directly owned by AstralBio, Inc., except to the extent of his direct ownership, pursuant to Rule 13d-4 of the Securities Exchange Act of 1934.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction beyond the details of the licensing agreement and share issuances.

Industry Context

This filing indicates a significant equity stake by the CEO of AstralBio, Inc., a company with which IBIO, Inc. has entered into an exclusive licensing agreement. This suggests a strategic partnership or collaboration in the biotechnology or pharmaceutical sector, potentially involving intellectual property or product development, which is a common trend in the industry for leveraging specialized expertise or expanding pipelines.

Related Party Transactions

• Patrick J. Crutcher, the Reporting Person, is the Chief Executive Officer and majority shareholder of AstralBio, Inc., which entered into an exclusive Licensing Agreement with IBIO, Inc. and received 264,087 shares of Common Stock. This constitutes a related party transaction due to Mr. Crutcher's dual role and indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The issuance of new shares to AstralBio and in private placements could lead to dilution of existing shareholders' ownership percentage. However, the underlying licensing agreement could also bring strategic value to the company.
• AstralBio, Inc.: Becomes a significant shareholder in IBIO, Inc., strengthening the partnership established by the exclusive licensing agreement.
• Patrick J. Crutcher: Increases his direct and indirect beneficial ownership in IBIO, Inc., aligning his interests with the company's performance, particularly given his role as CEO of AstralBio.

Key Dates

Keywords

IBIO, AstralBio, Patrick J. Crutcher, Schedule 13G, Beneficial Ownership, Common Stock, Licensing Agreement, Private Placement, SEC Filing, Biotechnology, Pharmaceuticals